COVID-19 Disease and Interferon-gamma: Has it a Protective Impact on Mortality?

Basit Öğe Kaydı
dc.authoridhttps://orcid.org/0000-0002-8861-7106en_US
dc.contributor.authorHusseini, Abbas Ali
dc.contributor.authorKamil, Anton Abdulbasah
dc.contributor.authorAloudal, Mohammad Reza
dc.date.accessioned2023-07-06T19:29:49Z
dc.date.available2023-07-06T19:29:49Z
dc.date.issued2021en_US
dc.departmentSağlık Hizmetleri Meslek Yüksekokuluen_US
dc.description.abstractThe complex coincidence of several immunopathological, socio-cultural, and health infrastructure factors may affect the COVID-19 related mortality among different populations. The impact of the age on disease progression has been confirmed in several studies. Recently limited ecological and clinical studies have sparked controversy among researchers about the protective impact of the non-specific effect of routinely used Bacille Calmette-Guerin (BCG), Hepatitis A virus (HAV), and influenza (Flu) vaccines or their natural infections against COVID-19. In the present study, variables, including BCG vaccination coverage, HAV prevalence, and population age distributions, from 59 countries were analyzed to examine their potential association with COVID-19 infection and related mortality rate. Concerning COVID-19 cases/million population (1MP) and mortality, there are significant differences between countries with and without BCG vaccination programs (p-value <0.001). A significant negative correlation between both BCG coverage and HAV prevalence with COVID-19 related mortality was also found (r (59)=-0.4, p-value <0.05), (r (59) =-0.3, p-value <0.01). Based on the results of the present study, previous ecological analyses and available epidemiological evidence, along with knowledge of the immune response to BCG, HAV and influenza vaccination, as well as COVID-19 infection progression, the current study suggest a hypothesis that IFN-? induced immune response which could be triggered by BCG, HAV, and flu vaccination or natural infections may have a protective effect against COVID-19 related mortality.en_US
dc.identifier.doi10.14744/etd.2020.40326en_US
dc.identifier.endpage121en_US
dc.identifier.issn2149-2247
dc.identifier.issn2149-2549
dc.identifier.issue2en_US
dc.identifier.startpage116en_US
dc.identifier.trdizinid486766en_US
dc.identifier.urihttps://hdl.handle.net/11363/4959
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/486766
dc.identifier.urihttps://doi.org/
dc.identifier.volume43en_US
dc.identifier.wosWOS:000626292700003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorHusseini, Abbas Ali
dc.institutionauthorKamil, Anton Abdulbasah
dc.language.isoenen_US
dc.publisherERCIYES UNIV SCH MEDICINE, ERCIYES UNIV TIP FAK 38039 MELIKGAZI, KAYSERI 00000, TURKEYen_US
dc.relation.ispartofErciyes Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectCOVID-19en_US
dc.subjectInterferon γen_US
dc.subjectmortalityen_US
dc.subjectBCGen_US
dc.subjectHAVen_US
dc.titleCOVID-19 Disease and Interferon-gamma: Has it a Protective Impact on Mortality?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
retrieve.pdf
Boyut:
250.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale / Article
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.56 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Web of Science ve Scopus Atıf Dizinlerindeki Yayınlar
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu